Analyzing Aditxt (NASDAQ:ADTX) & Heatwurx (NASDAQ:PCSA)
by Kim Johansen · The Markets DailyHeatwurx (NASDAQ:PCSA – Get Free Report) and Aditxt (NASDAQ:ADTX – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.
Earnings & Valuation
This table compares Heatwurx and Aditxt”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Heatwurx | N/A | N/A | -$13.56 million | ($9.29) | -0.23 |
| Aditxt | N/A | N/A | -$41.71 million | ($100,788.35) | 0.00 |
Heatwurx is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings for Heatwurx and Aditxt, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Heatwurx | 1 | 1 | 1 | 0 | 2.00 |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
Heatwurx presently has a consensus price target of $25.00, indicating a potential upside of 1,052.07%. Given Heatwurx’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Heatwurx is more favorable than Aditxt.
Risk & Volatility
Heatwurx has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500.Comparatively, Aditxt has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Profitability
This table compares Heatwurx and Aditxt’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Heatwurx | N/A | -281.31% | -200.80% |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
Institutional and Insider Ownership
91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 2.4% of Heatwurx shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Heatwurx beats Aditxt on 10 of the 12 factors compared between the two stocks.
About Heatwurx
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 for treatment of gastroparesis; and PCS499 to treat patients with ulcerative and non-ulcerative necrobiosis lipoidica. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2011 and is based in Hanover, Maryland.
About Aditxt
Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.